Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Double-Hit Lymphoma Outcomes Evaluated
J Clin Oncol; ePub 2017 May 5; Landsburg, et al
Use of consolidative autologous stem-cell transplantation (autoSCT) did not lead to improved relapse-free or overall survival in certain patients with double-hit lymphoma (DHL), according to a study involving 159 individuals.
Participants had DHL and achieved first complete remission after either 1) rituximab plus cyclophosphamide; doxorubicin, vincristine, and prednisone (R-CHOP); or 2) intensive front-line therapy. Among the results:
- At 3 years, relapse-free survival rate was 80%; overall survival was 87%.
- These rates were similar whether or not patients were treated with autoSCT.
- Relapse-free survival in patients receiving R-CHOP was 56%, vs 88% in those given intensive therapy.
- This rate was similar in R-CHOP and intensive therapy patients whether or not they received autoSCT.
- Median overall survival after relapse was 8.6 months.
Citation:
Landsburg D, Falkiewicz, Maly J, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. [Published online ahead of print May 5, 2017]. J Clin Oncol. doi:10.1200/JCO.2017.72.2157.